Basic Information
| LncRNA/CircRNA Name | RP11-79H23.3 |
| Synonyms | NA |
| Region | GRCh38_8:78837529-78840522 |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | bladder cancer |
| ICD-0-3 | C67 |
| Methods | Microarray, qPCR, Dual Luciferase Reporter Assay, RIP, Western blot |
| Sample | bladder cancer tissues, cell lines (EJ, T24, BIU87, SV-HUC-1) |
| Expression Pattern | down-regulated |
| Function Description | We found that lncRNA RP11-79H23.3 and phosphatase and tensin homolog (PTEN) were significantly downregulated in BC tissues and cells. we found that overexpression of RP11-79H23.3 could suppress cell proliferation, migration, and cell cycle progression, rearrange the cytoskeleton, and induce apoptosis in vitro. we identified that RP11-79H23.3 could directly bind to miR-107 and abolish the suppressive effect on target gene PTEN. |
| Pubmed ID | 30149689 |
| Year | 2018 |
| Title | LncRNA RP11-79H23.3 Functions as a Competing Endogenous RNA to Regulate PTEN Expression through Sponging hsa-miR-107 in the Development of Bladder Cancer. |
External Links
| Links for RP11-79H23.3 | GenBank HGNC NONCODE |
| Links for bladder cancer | OMIM COSMIC |